Company Overview - Lear Corporation is a Tier 1 supplier to the global automotive industry, providing automotive seating and electrical systems (E-Systems) [11] - The company serves major automotive original equipment manufacturers (OEMs) and operates in 38 countries [11] Investment Ratings - Lear Corporation has a Zacks Rank of 3 (Hold) and a VGM Score of A, indicating a solid overall rating [11] - The company has a Momentum Style Score of B, with shares increasing by 7.9% over the past four weeks [12] Earnings Estimates - For fiscal 2026, two analysts have revised their earnings estimates upwards in the last 60 days, with the Zacks Consensus Estimate increasing by $0.28 to $14.11 per share [12] - Lear Corporation has an average earnings surprise of +14.3%, suggesting a positive trend in earnings performance [12]

Company Overview - Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company headquartered in New Jersey, providing a broad range of products for food animals including poultry, swine, beef, dairy cattle, and aquaculture [11] - The company markets nearly 770 product lines in over 80 countries to approximately 4,000 customers, also manufacturing specific ingredients for personal care, automotive, industrial chemical, and chemical catalyst industries [11] Investment Rating - Phibro Animal Health is rated 2 (Buy) on the Zacks Rank, indicating a favorable investment outlook [12] - The company has a VGM Score of A, suggesting strong overall performance across value, growth, and momentum metrics [12] Momentum and Earnings Estimates - The Momentum Style Score for Phibro Animal Health is B, with shares having increased by 25.9% over the past four weeks, indicating strong upward price momentum [12] - For fiscal 2026, one analyst has revised their earnings estimate upwards in the last 60 days, with the Zacks Consensus Estimate increasing by $0.07 to $2.83 per share [12] - The company boasts an average earnings surprise of +20.2%, reflecting its ability to exceed earnings expectations [12] Conclusion - With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, Phibro Animal Health is positioned as a strong candidate for investors' short lists [13]

Company Overview - Kennametal Inc. is a manufacturer, marketer, and distributor of high-speed metal cutting tools, tooling systems, and wear-resistant parts, serving various industries including machine tools, transportation, aerospace, and oil and gas exploration [11]. Investment Highlights - Kennametal has a Zacks Rank of 1 (Strong Buy) and a VGM Score of B, indicating strong potential for investment [12]. - The company has a Momentum Style Score of A, with shares increasing by 27.5% over the past four weeks [12]. - For fiscal 2026, three analysts have revised their earnings estimates upwards, with the Zacks Consensus Estimate rising by $0.25 to $1.60 per share [12]. - Kennametal has an average earnings surprise of +35.4%, showcasing its ability to exceed earnings expectations [12]. Conclusion - With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, Kennametal is positioned as a strong candidate for investors [13].

Core Insights - Zacks Premium offers tools for investors to enhance their stock market strategies and confidence, including daily updates, research reports, and stock screens [1][2] Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum methodologies, helping investors identify stocks likely to outperform the market in the short term [2][3] - Stocks are rated from A to F, with A indicating the highest potential for outperformance [3] Value Score - The Value Style Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Cash Flow [3] Growth Score - The Growth Style Score assesses a company's financial health and future outlook by analyzing projected and historical earnings, sales, and cash flow [4] Momentum Score - The Momentum Style Score evaluates stocks based on price trends and earnings estimate changes, aiding investors in timing their positions in high-momentum stocks [5] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors who utilize multiple investing strategies [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to identify stocks, with 1 (Strong Buy) stocks achieving an average annual return of +23.83% since 1988, significantly outperforming the S&P 500 [7][8] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal success [9] Company Spotlight: Verizon Communications (VZ) - Verizon Communications Inc. is a leading provider of communication services in North America, having grown through mergers and acquisitions, including its merger with MCI Corporation and the acquisition of Alltel Wireless Corp. [11] - Verizon holds a Zacks Rank of 3 (Hold) and has a VGM Score of A, with a Momentum Style Score of A, reflecting a 16.1% increase in share price over the past four weeks [12] - Analysts have revised Verizon's earnings estimate upwards, with the Zacks Consensus Estimate increasing by $0.02 to $4.87 per share, and the company has an average earnings surprise of +2.9% [12][13]

Core Insights - Quest Diagnostics (DGX) is scheduled to release its fourth-quarter 2025 results on February 10, with adjusted earnings per share (EPS) of $2.60 in the last reported quarter, exceeding the Zacks Consensus Estimate by 3.59% [2] - The Zacks Consensus Estimate for Q4 revenues is $2.75 billion, reflecting a 4.8% increase year-over-year, while EPS is expected to rise by 5.4% to $2.35 [3] Q4 Estimates - The revenue estimate for Quest Diagnostics indicates a growth of 4.8% compared to the previous year [3] - The EPS estimate suggests a 5.4% increase from the prior year [3] Estimate Revision Trend - Estimates for Quest Diagnostics' Q4 earnings have remained stable over the past 30 days, indicating consistent expectations leading up to the announcement [4] Factors Influencing Q4 Results - The core Diagnostics Information Services (DIS) business is anticipated to show strong revenue growth due to organic growth in physician, hospital, and consumer channels [5] - The acquisition of clinical testing assets from Fresenius Medical Care is expected to positively impact physician channel revenues, contributing an estimated 2.8% to DIS revenues in Q4 [6] Advanced Diagnostics Performance - Robust revenue generation is expected in Advanced Diagnostics across various clinical areas, including cardiometabolic, endocrine, and autoimmune disease testing [7] - Growth in Brain Health is likely driven by AD-detect blood tests for assessing Alzheimer's disease risk [7] Collaborative Lab Solutions - Collaborative Lab Solutions may have contributed to growth in the hospital channel, with strategic partnerships enhancing access to diagnostic innovations [8] Revenue Growth Drivers - An enhanced questhealth.com platform is likely to have supported strong fourth-quarter revenues through partnerships with consumer health brands [10] - The DIS revenues are projected to increase by 4.7% year-over-year in Q4 [11] Operational Excellence - The company is expected to have continued expanding automation, robotics, and AI to improve quality and productivity, contributing to top-line growth [12] Earnings ESP and Zacks Rank - Quest Diagnostics has an Earnings ESP of 0.00%, indicating no expected surprise in earnings [13] - The company currently holds a Zacks Rank of 2 (Buy) [14]

Company Overview - Haemonetics Corporation provides blood management solutions to blood and plasma collectors, hospitals, and healthcare providers globally, offering integrated devices, information management, and consulting services to enhance clinical outcomes in the blood supply chain [11]. Investment Potential - Haemonetics is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of A, indicating a solid investment potential [12]. - The company has a Growth Style Score of B, forecasting a year-over-year earnings growth of 8.1% for the current fiscal year, with a recent upward revision in earnings estimates [12]. - The Zacks Consensus Estimate for Haemonetics has increased by $0.01 to $4.94 per share, and the company has an average earnings surprise of +6.8% [12]. Recommendation - With a strong Zacks Rank and favorable Growth and VGM Style Scores, Haemonetics is recommended for investors looking for growth opportunities [13].

Company Overview - Huntington Ingalls Industries (HII) is based in Newport News, VA, and specializes in designing, building, and maintaining nuclear-powered ships, including aircraft carriers and submarines, as well as non-nuclear ships for the U.S. Navy and Coast Guard [11] - The company also provides after-market services for military ships globally [11] Investment Ratings - HII holds a Zacks Rank of 2 (Buy) and has a VGM Score of A, indicating strong potential for investment [11] - The company is considered a top pick for growth investors due to its favorable ratings [12] Growth Potential - HII has a Growth Style Score of B, with a forecasted year-over-year earnings growth of 12.4% for the current fiscal year [12] - In the last 60 days, five analysts have revised their earnings estimates higher for fiscal 2026, with the Zacks Consensus Estimate increasing by $0.18 to $17.30 per share [12] - HII has an average earnings surprise of +17.7%, further indicating its strong performance potential [12]

Company Overview - Moelis & Company is a global investment bank headquartered in New York, providing strategic and financial advisory services across various sectors, including mergers and acquisitions, capital market activities, restructurings, and corporate finance transactions involving public and private debt and equity [11]. Investment Ratings - Moelis has a Zacks Rank of 3 (Hold) and a VGM Score of B, indicating a moderate investment outlook [12]. - The company is considered a potential top pick for growth investors due to its Growth Style Score of B, forecasting a year-over-year earnings growth of 14.7% for the current fiscal year [12]. Earnings Estimates - In the last 60 days, three analysts have revised their earnings estimates upwards for fiscal 2026, with the Zacks Consensus Estimate increasing by $0.10 to $3.43 per share [12]. - Moelis has demonstrated an average earnings surprise of +36.5%, suggesting strong performance relative to expectations [12]. Investment Considerations - With a solid Zacks Rank and favorable Growth and VGM Style Scores, Moelis should be considered for inclusion in investors' portfolios [13].

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies and confidence in investing [1] Zacks Style Scores - Zacks Style Scores are indicators that assist investors in selecting stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [2] Value Score - The Value Style Score focuses on identifying undervalued stocks by analyzing ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow to highlight attractive investment opportunities [3] Growth Score - The Growth Style Score evaluates a company's future prospects and financial health by analyzing projected and historical earnings, sales, and cash flow to identify stocks with sustainable growth potential [4] Momentum Score - The Momentum Style Score helps investors capitalize on price trends by assessing one-week price changes and monthly earnings estimate changes, indicating favorable times to invest in high-momentum stocks [5] VGM Score - The VGM Score combines the three Style Scores to identify stocks with the best value, growth forecasts, and momentum, serving as a strong indicator alongside the Zacks Rank [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify the process of building a successful investment portfolio [7] Performance of Zacks Rank - Stocks rated 1 (Strong Buy) have achieved an average annual return of +23.83% since 1988, significantly outperforming the S&P 500 [8] Stock Selection Strategy - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B, while also considering stocks with a 3 (Hold) rank that have similar scores for potential upside [9] Earnings Outlook Importance - Changes in a company's earnings outlook are crucial for stock selection; stocks with lower ranks but high Style Scores may still face downward price trends [10] Company Spotlight: Palantir Technologies Inc. - Palantir Technologies, founded in 2003, specializes in software platforms for the intelligence community, currently holding a Zacks Rank of 2 (Buy) and a VGM Score of B [11] Growth Potential of Palantir - Palantir has a Growth Style Score of A, with a projected year-over-year earnings growth of 78.7% for the current fiscal year, and has seen upward revisions in earnings estimates [12]

Core Insights - Zacks Premium provides tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1] Zacks Style Scores - Zacks Style Scores are indicators that help investors select stocks likely to outperform the market in the next 30 days, rated from A to F based on value, growth, and momentum characteristics [2] - The Value Score focuses on identifying undervalued stocks using ratios like P/E, PEG, and Price/Sales [3] - The Growth Score assesses a company's financial health and future outlook through projected and historical earnings, sales, and cash flow [4] - The Momentum Score identifies optimal times to invest based on price trends and earnings estimate changes [5] - The VGM Score combines all three Style Scores, providing a comprehensive indicator for stock selection [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investors, with 1 (Strong Buy) stocks achieving an average annual return of +23.83% since 1988, significantly outperforming the S&P 500 [7] - There are over 800 stocks rated 1 or 2, making it essential for investors to utilize Style Scores to narrow down choices [8] - For optimal returns, stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B are recommended [9] - Stocks with lower ranks but high Style Scores may still face downward price pressure due to negative earnings forecasts [10] Company Spotlight: Align Technology - Align Technology, based in California, specializes in clear aligner therapy and digital services for dentistry [11] - The company holds a Zacks Rank of 2 (Buy) and a VGM Score of B, with a Value Style Score of B, supported by a forward P/E ratio of 15.93 [12] - Recent upward revisions in earnings estimates and a Zacks Consensus Estimate of $11.02 per share for fiscal 2026 highlight its potential [12] - With strong rankings and favorable Style Scores, Align Technology is positioned as a compelling investment opportunity [13]